Trial Profile

OPEN-LABEL INDUCTION AND MAINTENANCE STUDY OF ORAL CP-690,550 (TOFACITINIB) IN CHILDREN WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 12 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tofacitinib (Primary)
Indications Ulcerative colitis
Focus Registrational; Therapeutic Use
Sponsors Pfizer

Most Recent Events

03 Aug 2026 Planned End Date changed from 4 Jul 2029 to 6 Jun 2029.
03 Aug 2026 Planned primary completion date changed from 14 Apr 2027 to 17 Mar 2027.
02 Jun 2026 Planned End Date changed from 18 Jul 2029 to 4 Jul 2029.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com